Lp(a): from causality to therapy

Episodes 1-3 of 3

• 

  RestartResume

  Targeting Lp(a): therapeutic insights and novel developments

  RestartResume

  Targeting Lp(a): therapeutic insights and novel developments

  Lp(a): from causality to therapy

  Targeting Lp(a): therapeutic insights and novel developments

  • 

    Prof. Erik Stroes, MD

• 

  RestartResume

  Lp(a) as independent causal risk factor: why should we focus on testing?

  RestartResume

  Lp(a) as independent causal risk factor: why should we focus on testing?

  Lp(a): from causality to therapy

  Lp(a) as independent causal risk factor: why should we focus on testing?

  • 

    Prof. Florian Kronenberg, MD

• 

  RestartResume

  Targeting Lp(a) in CV risk reduction: where are we now?

  RestartResume

  Targeting Lp(a) in CV risk reduction: where are we now?

  Lp(a): from causality to therapy

  Targeting Lp(a) in CV risk reduction: where are we now?

  • 

    Pia Kamstrup, MD, PhD